Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer

Int J Mol Sci. 2023 Feb 16;24(4):3988. doi: 10.3390/ijms24043988.

Abstract

Radiogenomic heterogeneity features in 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) have become popular in non-small cell lung cancer (NSCLC) research. However, the reliabilities of genomic heterogeneity features and of PET-based glycolytic features in different image matrix sizes have yet to be thoroughly tested. We conducted a prospective study with 46 NSCLC patients to assess the intra-class correlation coefficient (ICC) of different genomic heterogeneity features. We also tested the ICC of PET-based heterogeneity features from different image matrix sizes. The association of radiogenomic features with clinical data was also examined. The entropy-based genomic heterogeneity feature (ICC = 0.736) is more reliable than the median-based feature (ICC = -0.416). The PET-based glycolytic entropy was insensitive to image matrix size change (ICC = 0.958) and remained reliable in tumors with a metabolic volume of <10 mL (ICC = 0.894). The glycolytic entropy is also significantly associated with advanced cancer stages (p = 0.011). We conclude that the entropy-based radiogenomic features are reliable and may serve as ideal biomarkers for research and further clinical use for NSCLC.

Keywords: 18F-FDG PET; lung cancer; molecular imaging; tumor heterogeneity; whole exome sequencing.

MeSH terms

  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Entropy
  • Fluorodeoxyglucose F18
  • Genomics
  • Humans
  • Lung Neoplasms* / metabolism
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography / methods
  • Prospective Studies
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18
  • Biomarkers